Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia

Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival

(2012) Veronika Bachanova et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation

(2012) C.-H. Yan et al.   BLOOD

Minimal residual disease monitoring in childhood acute lymphoblastic leukemia

(2012) Dario Campana   CURRENT OPINION IN HEMATOLOGY

Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP–EBMT analysis

(2012) A Ruggeri et al.   LEUKEMIA

Clinical significance of minimal residual disease detected by multidimensional flow cytometry: Serial monitoring after allogeneic stem cell transplantation for acute leukemia

(2012) Takuya Miyazaki et al.   LEUKEMIA RESEARCH

High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia

(2012) D. Wu et al.   Science Translational Medicine

Acute Lymphoblastic Leukemia: Monitoring Minimal Residual Disease as a Therapeutic Principle

(2012) Monika Brüggemann et al.   SEMINARS IN ONCOLOGY

High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia

(2011) W. Leung et al.   BLOOD

The GTPase-activating protein ARAP3 regulates chemotaxis and adhesion-dependent processes in neutrophils

(2011) L. Gambardella et al.   BLOOD

Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation

(2011) E. Rettinger et al.   BLOOD

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

(2011) F. Buccisano et al.   BLOOD

Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation

(2011) Min Fang et al.   CANCER

Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

(2011) Alida Dominietto   CURRENT OPINION IN HEMATOLOGY

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia

(2011) R. Ram et al.   HAEMATOLOGICA

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

(2011) U Platzbecker et al.   LEUKEMIA

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, Acute Leukemias, and Myelodysplastic Syndromes

(2010) Nicolaus Kröger et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Minimal Residual Disease following Allogeneic Hematopoietic Stem Cell Transplantation

(2010) Nicolaus Kröger et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Allogeneic Hematopoietic Cell Transplantation with Full-Intensity Conditioning for Adult Acute Lymphoblastic Leukemia: Results from a Single Center, 1998-2006

(2010) Kristine Doney et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia

(2010) S. Giebel et al.   BLOOD

Towards individualized follow-up in adult acute myeloid leukemia in remission

(2010) P. Hokland et al.   BLOOD

Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia

(2010) Anna Candoni et al.   CLINICAL TRANSPLANTATION

Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia

(2010) I. Elorza et al.   HAEMATOLOGICA

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia

(2010) Boglarka Gyurkocza et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation

(2010) A C Lankester et al.   LEUKEMIA

Progress of Minimal Residual Disease Studies in Childhood Acute Leukemia

(2010) Dario Campana   Current Hematologic Malignancy Reports

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

(2009) R. Bassan et al.   BLOOD

Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL

(2009) S Giebel et al.   BONE MARROW TRANSPLANTATION

HighWT1gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival

(2009) David A. Jacobsohn et al.   BRITISH JOURNAL OF HAEMATOLOGY

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993

(2009) Bella Patel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation

(2009) M. Bornhauser et al.   HAEMATOLOGICA

Role of Minimal Residual Disease Monitoring in Adult and Pediatric Acute Lymphoblastic Leukemia

(2009) Dario Campana   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy

(2009) David Grimwade et al.   JOURNAL OF CLINICAL ONCOLOGY

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

(2009) M Brüggemann et al.   LEUKEMIA

Monitoring of post-transplant remission of childhood malignancies: is there a standard?

(2008) P Bader et al.   BONE MARROW TRANSPLANTATION

Minimal residual disease diagnostics in myeloid malignancies in the post transplant period

(2008) U Bacher et al.   BONE MARROW TRANSPLANTATION

Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid Leukemia

(2008) Luca Maurillo et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group

(2008) Peter Bader et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute lymphoblastic leukaemia

(2008) Ching-Hon Pui et al.   LANCET

Minimal residual disease is an important predictive factor of outcome in children with relapsed ‘high-risk’ acute lymphoblastic leukemia

(2008) M Paganin et al.   LEUKEMIA